Clinical Trial Results:
A pilot study to assess the efficacy of intravenous iron isomaltoside 1000 (Monofer®) in the management of anaemia associated with the palliative management of upper gastrointestinal adenocarcinoma
Summary
|
|
EudraCT number |
2013-000209-22 |
Trial protocol |
GB |
Global end of trial date |
28 Aug 2017
|
Results information
|
|
Results version number |
v1(current) |
This version publication date |
22 Sep 2018
|
First version publication date |
22 Sep 2018
|
Other versions |
|
Summary report(s) |
End of study report |
Trial Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information
|
|||
Trial identification
|
|||
Sponsor protocol code |
12GA029
|
||
Additional study identifiers
|
|||
ISRCTN number |
- | ||
US NCT number |
NCT01927328 | ||
WHO universal trial number (UTN) |
- | ||
Sponsors
|
|||
Sponsor organisation name |
Nottingham University Hospitals NHS Trust
|
||
Sponsor organisation address |
Derby Road, Nottingham, United Kingdom,
|
||
Public contact |
Austin Acheson, Nottingham University Hospitals NHS Trust , +44 01159249924, researchsponsor@nuh.nhs.uk
|
||
Scientific contact |
Austin Acheson, Nottingham University Hospitals NHS Trust , +44 01159249924, researchsponsor@nuh.nhs.uk
|
||
Paediatric regulatory details
|
|||
Is trial part of an agreed paediatric investigation plan (PIP) |
No
|
||
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial? |
No
|
||
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial? |
No
|
||
Results analysis stage
|
|||
Analysis stage |
Final
|
||
Date of interim/final analysis |
28 Aug 2017
|
||
Is this the analysis of the primary completion data? |
Yes
|
||
Primary completion date |
28 Aug 2017
|
||
Global end of trial reached? |
Yes
|
||
Global end of trial date |
28 Aug 2017
|
||
Was the trial ended prematurely? |
No
|
||
General information about the trial
|
|||
Main objective of the trial |
To determine the feasibility of a larger trial, ie determine study size, ensure logistics adequate, to review patient uptake etc.
|
||
Protection of trial subjects |
The study was conducted in full conformity with the current revision of the Declaration of Helsinki (last amended October 2000, with additional footnotes added 2002 and 2004).
The study was conducted in full conformity with relevant regulations and with the ICH Guidelines for Good Clinical Practice (CPMP/ICH/135/95) July 1996.
The protocol, informed consent form, participant information sheet and all substantial amendments to the original approved documents were submitted to the Research Ethics Committee (REC), regulatory authorities (MHRA in the UK), and host institution(s) and received formal written approval.
The study was conducted in accordance with GCP principles and NUH processes.
|
||
Background therapy |
- | ||
Evidence for comparator |
- | ||
Actual start date of recruitment |
07 Jul 2013
|
||
Long term follow-up planned |
No
|
||
Independent data monitoring committee (IDMC) involvement? |
No
|
||
Population of trial subjects
|
|||
Number of subjects enrolled per country |
|||
Country: Number of subjects enrolled |
United Kingdom: 27
|
||
Worldwide total number of subjects |
27
|
||
EEA total number of subjects |
27
|
||
Number of subjects enrolled per age group |
|||
In utero |
0
|
||
Preterm newborn - gestational age < 37 wk |
0
|
||
Newborns (0-27 days) |
0
|
||
Infants and toddlers (28 days-23 months) |
0
|
||
Children (2-11 years) |
0
|
||
Adolescents (12-17 years) |
0
|
||
Adults (18-64 years) |
0
|
||
From 65 to 84 years |
27
|
||
85 years and over |
0
|
|
|||||||||||||||||||
Recruitment
|
|||||||||||||||||||
Recruitment details |
Patients were identified from the oesophagogastric MDT meetings. Included were adult patients with a proven histological diagnosis of oesophagogastric adenocarcinoma, anaemia (<12 g/dL in women and <13 g/dL in men) and a treatment decision for palliative chemotherapy. | ||||||||||||||||||
Pre-assignment
|
|||||||||||||||||||
Screening details |
Patients were randomised 1:1 to each group using random allocations concealed in opaque envelopes. Patients in the control arm had their anaemia managed by traditional regimens as decided by the clinical oncology team. The patients in the intravenous iron group received intravenous iron isomaltoside 1000 (Monofer ®). Doses were calculated using the | ||||||||||||||||||
Pre-assignment period milestones
|
|||||||||||||||||||
Number of subjects started |
27 | ||||||||||||||||||
Number of subjects completed |
27 | ||||||||||||||||||
Period 1
|
|||||||||||||||||||
Period 1 title |
Recruitment
|
||||||||||||||||||
Is this the baseline period? |
Yes | ||||||||||||||||||
Allocation method |
Randomised - controlled
|
||||||||||||||||||
Blinding used |
Not blinded | ||||||||||||||||||
Blinding implementation details |
N/A
|
||||||||||||||||||
Arms
|
|||||||||||||||||||
Are arms mutually exclusive |
Yes
|
||||||||||||||||||
Arm title
|
Intravenous iron | ||||||||||||||||||
Arm description |
Intravenous Iron Isomaltoside 1000 (Monofer ®) (IIM) | ||||||||||||||||||
Arm type |
Experimental | ||||||||||||||||||
Investigational medicinal product name |
Iron Isomaltoside 1000 (Monofer ®)
|
||||||||||||||||||
Investigational medicinal product code |
|||||||||||||||||||
Other name |
|||||||||||||||||||
Pharmaceutical forms |
Solution for infusion
|
||||||||||||||||||
Routes of administration |
Intravenous drip use
|
||||||||||||||||||
Dosage and administration details |
The study intervention treatment is intravenous Iron Isomaltoside 1000 (Monofer ®) (IIM). It will be administered in line with the product Summary of Product Characteristics Guidelines (SPC). Doses will be calculated by the Ganzoni equation of cumulative iron deficit. To replenish iron stores by a single infusion, doses up to 20mg/kg body weight of iron may be administered per week. The IIM is diluted in 250ml 0.9% sodium chloride and infused over a period of 60 minutes. The patient will be observed by clinical staff during the administration of the drug.
|
||||||||||||||||||
Arm title
|
Standard care | ||||||||||||||||||
Arm description |
Standard clinical care as per the treating physician | ||||||||||||||||||
Arm type |
No intervention | ||||||||||||||||||
Investigational medicinal product name |
No investigational medicinal product assigned in this arm
|
||||||||||||||||||
|
|||||||||||||||||||
Period 2
|
|||||||||||||||||||
Period 2 title |
Cycle 1 chemotherapy
|
||||||||||||||||||
Is this the baseline period? |
No | ||||||||||||||||||
Allocation method |
Randomised - controlled
|
||||||||||||||||||
Blinding used |
Not blinded | ||||||||||||||||||
Blinding implementation details |
N/A
|
||||||||||||||||||
Arms
|
|||||||||||||||||||
Are arms mutually exclusive |
Yes
|
||||||||||||||||||
Arm title
|
Intravenous iron | ||||||||||||||||||
Arm description |
Intravenous Iron Isomaltoside 1000 (Monofer ®) (IIM) | ||||||||||||||||||
Arm type |
Experimental | ||||||||||||||||||
Investigational medicinal product name |
Iron Isomaltoside 1000 (Monofer ®)
|
||||||||||||||||||
Investigational medicinal product code |
|||||||||||||||||||
Other name |
|||||||||||||||||||
Pharmaceutical forms |
Solution for infusion
|
||||||||||||||||||
Routes of administration |
Intravenous drip use
|
||||||||||||||||||
Dosage and administration details |
The study intervention treatment is intravenous Iron Isomaltoside 1000 (Monofer ®) (IIM). It will be administered in line with the product Summary of Product Characteristics Guidelines (SPC). Doses will be calculated by the Ganzoni equation of cumulative iron deficit. To replenish iron stores by a single infusion, doses up to 20mg/kg body weight of iron may be administered per week. The IIM is diluted in 250ml 0.9% sodium chloride and infused over a period of 60 minutes. The patient will be observed by clinical staff during the administration of the drug.
|
||||||||||||||||||
Arm title
|
Standard care | ||||||||||||||||||
Arm description |
Standard clinical care as per the treating physician | ||||||||||||||||||
Arm type |
No intervention | ||||||||||||||||||
Investigational medicinal product name |
No investigational medicinal product assigned in this arm
|
||||||||||||||||||
|
|||||||||||||||||||
Period 3
|
|||||||||||||||||||
Period 3 title |
Cycle 2 chemotherapy
|
||||||||||||||||||
Is this the baseline period? |
No | ||||||||||||||||||
Allocation method |
Randomised - controlled
|
||||||||||||||||||
Blinding used |
Not blinded | ||||||||||||||||||
Blinding implementation details |
N/A
|
||||||||||||||||||
Arms
|
|||||||||||||||||||
Are arms mutually exclusive |
Yes
|
||||||||||||||||||
Arm title
|
Intravenous iron | ||||||||||||||||||
Arm description |
Intravenous Iron Isomaltoside 1000 (Monofer ®) (IIM) | ||||||||||||||||||
Arm type |
Experimental | ||||||||||||||||||
Investigational medicinal product name |
Iron Isomaltoside 1000 (Monofer ®)
|
||||||||||||||||||
Investigational medicinal product code |
|||||||||||||||||||
Other name |
|||||||||||||||||||
Pharmaceutical forms |
Solution for infusion
|
||||||||||||||||||
Routes of administration |
Intravenous drip use
|
||||||||||||||||||
Dosage and administration details |
The study intervention treatment is intravenous Iron Isomaltoside 1000 (Monofer ®) (IIM). It will be administered in line with the product Summary of Product Characteristics Guidelines (SPC). Doses will be calculated by the Ganzoni equation of cumulative iron deficit. To replenish iron stores by a single infusion, doses up to 20mg/kg body weight of iron may be administered per week. The IIM is diluted in 250ml 0.9% sodium chloride and infused over a period of 60 minutes. The patient will be observed by clinical staff during the administration of the drug.
|
||||||||||||||||||
Arm title
|
Standard care | ||||||||||||||||||
Arm description |
Standard clinical care as per the treating physician | ||||||||||||||||||
Arm type |
No intervention | ||||||||||||||||||
Investigational medicinal product name |
No investigational medicinal product assigned in this arm
|
||||||||||||||||||
|
|||||||||||||||||||
Period 4
|
|||||||||||||||||||
Period 4 title |
Cycle 3 chemotherapy
|
||||||||||||||||||
Is this the baseline period? |
No | ||||||||||||||||||
Allocation method |
Randomised - controlled
|
||||||||||||||||||
Blinding used |
Not blinded | ||||||||||||||||||
Blinding implementation details |
N/A
|
||||||||||||||||||
Arms
|
|||||||||||||||||||
Are arms mutually exclusive |
Yes
|
||||||||||||||||||
Arm title
|
Intravenous iron | ||||||||||||||||||
Arm description |
Intravenous Iron Isomaltoside 1000 (Monofer ®) (IIM) | ||||||||||||||||||
Arm type |
Experimental | ||||||||||||||||||
Investigational medicinal product name |
Iron Isomaltoside 1000 (Monofer ®)
|
||||||||||||||||||
Investigational medicinal product code |
|||||||||||||||||||
Other name |
|||||||||||||||||||
Pharmaceutical forms |
Solution for infusion
|
||||||||||||||||||
Routes of administration |
Intravenous drip use
|
||||||||||||||||||
Dosage and administration details |
The study intervention treatment is intravenous Iron Isomaltoside 1000 (Monofer ®) (IIM). It will be administered in line with the product Summary of Product Characteristics Guidelines (SPC). Doses will be calculated by the Ganzoni equation of cumulative iron deficit. To replenish iron stores by a single infusion, doses up to 20mg/kg body weight of iron may be administered per week. The IIM is diluted in 250ml 0.9% sodium chloride and infused over a period of 60 minutes. The patient will be observed by clinical staff during the administration of the drug.
|
||||||||||||||||||
Arm title
|
Standard care | ||||||||||||||||||
Arm description |
Standard clinical care as per the treating physician | ||||||||||||||||||
Arm type |
No intervention | ||||||||||||||||||
Investigational medicinal product name |
No investigational medicinal product assigned in this arm
|
||||||||||||||||||
|
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Baseline characteristics reporting groups
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Intravenous iron
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
Intravenous Iron Isomaltoside 1000 (Monofer ®) (IIM) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Standard care
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
Standard clinical care as per the treating physician | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
|||
End points reporting groups
|
|||
Reporting group title |
Intravenous iron
|
||
Reporting group description |
Intravenous Iron Isomaltoside 1000 (Monofer ®) (IIM) | ||
Reporting group title |
Standard care
|
||
Reporting group description |
Standard clinical care as per the treating physician | ||
Reporting group title |
Intravenous iron
|
||
Reporting group description |
Intravenous Iron Isomaltoside 1000 (Monofer ®) (IIM) | ||
Reporting group title |
Standard care
|
||
Reporting group description |
Standard clinical care as per the treating physician | ||
Reporting group title |
Intravenous iron
|
||
Reporting group description |
Intravenous Iron Isomaltoside 1000 (Monofer ®) (IIM) | ||
Reporting group title |
Standard care
|
||
Reporting group description |
Standard clinical care as per the treating physician | ||
Reporting group title |
Intravenous iron
|
||
Reporting group description |
Intravenous Iron Isomaltoside 1000 (Monofer ®) (IIM) | ||
Reporting group title |
Standard care
|
||
Reporting group description |
Standard clinical care as per the treating physician |
|
||||||||||||||||||||||
End point title |
Blood transfusions | |||||||||||||||||||||
End point description |
||||||||||||||||||||||
End point type |
Primary
|
|||||||||||||||||||||
End point timeframe |
At each cycle of chemotherapy
|
|||||||||||||||||||||
|
||||||||||||||||||||||
Statistical analysis title |
Chi squared | |||||||||||||||||||||
Comparison groups |
Intravenous iron v Standard care v Intravenous iron v Standard care v Intravenous iron v Standard care
|
|||||||||||||||||||||
Number of subjects included in analysis |
58
|
|||||||||||||||||||||
Analysis specification |
Pre-specified
|
|||||||||||||||||||||
Analysis type |
equivalence | |||||||||||||||||||||
P-value |
= 0.594 | |||||||||||||||||||||
Method |
Chi-squared | |||||||||||||||||||||
Confidence interval |
|
|||||||||||||||||||||||||||||
End point title |
Haemoglobin | ||||||||||||||||||||||||||||
End point description |
|||||||||||||||||||||||||||||
End point type |
Secondary
|
||||||||||||||||||||||||||||
End point timeframe |
Haemoglobin at each cycle of chemotherapy
|
||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||||||||||||
End point title |
Ferritin | ||||||||||||||||||||||||||||
End point description |
|||||||||||||||||||||||||||||
End point type |
Secondary
|
||||||||||||||||||||||||||||
End point timeframe |
At each cycle of chemotherapy
|
||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||||||||||||
End point title |
Transferrin saturations | ||||||||||||||||||||||||||||
End point description |
|||||||||||||||||||||||||||||
End point type |
Secondary
|
||||||||||||||||||||||||||||
End point timeframe |
At each cycle of chemotherapy
|
||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||
No statistical analyses for this end point |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Adverse events information
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Timeframe for reporting adverse events |
At each cycle of chemotherapy
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Assessment type |
Systematic | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dictionary used for adverse event reporting
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dictionary name |
MedDRA | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dictionary version |
1
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting groups
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Intravenous iron
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
Intravenous Iron Isomaltoside 1000 (Monofer ®) (IIM) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Standard care
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
Standard clinical care as per the treating physician | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Frequency threshold for reporting non-serious adverse events: 5% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
|||
Substantial protocol amendments (globally) |
|||
Were there any global substantial amendments to the protocol? No | |||
Interruptions (globally) |
|||
Were there any global interruptions to the trial? No | |||
Limitations and caveats |
|||
Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data. | |||
None reported |